Evidence map›Paper›PMID 42384311›Full record

Observational studyAnnals of nuclear medicine2026

The Prognostic Value of

Xingting Chen, Yumeng Peng, Qingming Zheng, Yuxin Lai, Hongfei Cheng, Zhaohui Zhu, Guochang Wang, Jie Zang

Registry-linked trialAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03780075 (Lu177-EB-PSMA617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients With Castration-Resistant Prostate Cancer), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03780075 phase1unknown statusnot on this map

Lu177-EB-PSMA617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients With Castration-Resistant Prostate Cancer

TypeinterventionalSponsorPeking Union Medical College HospitalRan2018 to 2022Enrolled50ConditionsMetastatic Castration-resistant Prostate CancerArms1.11GBq of 177Lu-EB-PSMA-617, 2.00 GBq of 177Lu-EB-PSMA-617, 3.70GBq of 177Lu-EB-PSMA-617
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xingting ChenSchool of Medical Imaging, Fujian Medical University, Fuzhou, 350122, China.
Yumeng PengDepartment of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University, No. 20 Chazhong Road Taijiang District, Fuzhou, 350005, China.
Qingming ZhengSchool of Medical Imaging, Fujian Medical University, Fuzhou, 350122, China.
Yuxin LaiDepartment of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University, No. 20 Chazhong Road Taijiang District, Fuzhou, 350005, China.
Hongfei ChengDepartment of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University, No. 20 Chazhong Road Taijiang District, Fuzhou, 350005, China.
Zhaohui ZhuDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.
Guochang WangDepartment of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University, No. 20 Chazhong Road Taijiang District, Fuzhou, 350005, China.
Jie ZangDepartment of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University, No. 20 Chazhong Road Taijiang District, Fuzhou, 350005, China. 15901495106@163.com.ORCID http://orcid.org/0009-0002-8281-9177

Funding

National Natural Science Foundation of China 82202200National Natural Science Foundation of China 82402315
6 · The paper itself

Abstract

backgroundWe aimed to explore the value of prostate-specific membrane antigen (PSMA) and

methodsThis study retrospectively enrolled 35 mCRPC patients who received

resultsAmong the 35 patients, 27 and 15 received 2 and 3 cycles of

conclusion

trial registrationClinicalTrials.gov, NCT03780075, Registered 19 December 2019, retrospectively registered, https://clinicaltrials.gov/study/NCT03780075.

Indexed as

DipeptidesEdetic AcidFluorodeoxyglucose F18Heterocyclic Compounds, 1-RingLutetiumPositron Emission Tomography Computed TomographyProstatic Neoplasms, Castration-ResistantRadioisotopesAgedAged, 80 and overGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedNeoplasm MetastasisDipeptidesEdetic AcidFluorodeoxyglucose F18gallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesHeterocyclic Compounds, 1-RingLutetiumLutetium-177lutetium (177Lu) vipivotide tetraxetanProstate-Specific AntigenRadioisotopes177Lu-EB-PSMA18F-FDG68Ga-PSMARadioligand therapy

Identifiers

PMID42384311

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.